12 results
8-K
EX-99.1
IGMS
IGM Biosciences Inc
4 Nov 21
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
9:30am
of four planned FOLFIRI combination dose escalation cohorts (3.0 mg/kg Q2W).
No acute or chronic clinically significant liver toxicity or clinically … months without showing signs of any chronic toxicities to date. No patient has discontinued treatment for drug related safety reasons
8-K
EX-99.1
IGMS
IGM Biosciences Inc
6 May 21
IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update
4:14pm
, for the treatment of non-Hodgkin’s lymphoma (NHL) and potentially other CD20-expressing hematologic malignancies, including chronic lymphocytic leukemia (CLL
S-1/A
IGMS
IGM Biosciences Inc
3 Sep 19
IPO registration (amended)
6:08am
of patients with CD20-positive cancer. CD20 is a protein commonly expressed on the surface of NHL cells and chronic lymphocytic leukemia (CLL) cells … for the treatment of patients with CD20-positive cancer. CD20 is a protein commonly expressed on the surface of NHL cells and chronic lymphocytic leukemia
DRS/A
IGMS
IGM Biosciences Inc
9 Aug 19
Draft registration statement (amended)
12:00am
of patients with CD20-positive cancer. CD20 is a protein commonly expressed on the surface of NHL cells and chronic lymphocytic leukemia (CLL) cells, while CD3 … antibody for the treatment of patients with CD20-positive cancer. CD20 is a protein commonly expressed on the surface of NHL cells and chronic lymphocytic
S-1
y4uyigyvqpxn54b
19 Aug 19
IPO registration
5:25pm
424B4
nwmarjzzstw
18 Sep 19
Prospectus supplement with pricing info
4:43pm
10-K
0ljmpz4vk 4w2
26 Mar 20
Annual report
4:01pm
DRS
r4q hhhz2p
28 Jun 19
Draft registration statement
12:00am
- Prev
- 1
- Next